Jaguar Health, Inc. (JAGX): Entry into a Material Definitive Agreement
Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0001585608 0001585608 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17,
How this was made
The 30-second read
Why it matters
Amendments delete/replace key royalty provisions to (i) set a $750,000 monthly payment floor (or greater of floor vs actual royalty entitlement) starting Oct. 1, 2026 for Uptown, and (ii) extend Streeterville monthly payment initiation from July 1, 2026 to Oct. 1, 2026. Separately, the Streeterville secured note maturity is extended to Oct. 1, 2026. The filing also describes additional preferred-to-common exchanges with Streeterville that, in aggregate, exceed 5% of issued and outstanding common shares (per the referenced 10-Q).
Market read
This is a financing-structure update: royalty payment floors and start-date extensions plus additional preferred-to-common exchanges can shift cash-flow timing and dilution expectations.
What to watch
Traders may overreact to the exchange-related share issuance; the key is whether the amended royalty terms materially improve net cash economics versus prior schedules, which is not fully quantified in the excerpt.
Background
Jaguar Health has existing royalty interests with Uptown and Streeterville and a secured note with Streeterville via its wholly owned subsidiary Napo; this 8-K reports amendments and related exchange transactions.
Ticker impact
Jaguar Health entered amendments to its Uptown and Streeterville royalty interests, resetting monthly payments to a $750k floor and extending initiation to Oct. 1, 2026.
Likely modest, with focus on financing/dilution optics rather than immediate cash benefit given payments begin Oct. 1, 2026.
The filing is primary-source and company-specific, but it provides no disclosed valuation, total proceeds, or immediate liquidity improvement; it mainly changes payment terms and extends maturities while also describing additional common-stock issuance in exchanges.
Market effects
Highlights ongoing structured-credit/royalty financing dynamics common in small-cap biopharma, where payment floors and start-date shifts can influence perceived funding runway.
None specific beyond Nasdaq small-cap sentiment.
Limited; transaction is bilateral with private capital providers and company-specific.
Counterpoint
The $750k payment floor could stabilize future royalty cash flows, potentially reducing downside risk versus variable royalties—positive for longer-dated holders.
Key entities
- issuerJaguar Health, Inc.
Nasdaq-listed company filing the 8-K; subject of the royalty and note amendments and related exchange issuances.
- counterpartyUptown Capital, LLC
Counterparty to the Uptown 2020 royalty interest amendment resetting monthly royalty payments to a $750k floor starting Oct. 1, 2026.
- counterpartyStreeterville Capital, LLC
Counterparty to the Streeterville 2022 royalty interest amendment extending payment initiation to Oct. 1, 2026 and to the secured note amendment extending maturity to Oct. 1, 2026; also receives common stock in preferred exchanges.
- subsidiaryNapo Pharmaceuticals, Inc.
Wholly owned subsidiary (Borrower) that amends the secured promissory note with Streeterville.
